1. The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect.
- Author
-
Buechler HM, Sumi M, Madhuranthakam IM, Donegan C, DiGiorgio F Jr, Acosta AA, Uribe S, Rahman MA, Sorbello A, Fischer BD, and Keck TM
- Subjects
- Animals, Male, Mice, Allosteric Regulation drug effects, Mice, Inbred C57BL, Alcoholism drug therapy, Pyridines pharmacology, Pyridines administration & dosage, Alcohol Drinking psychology, Phenylurea Compounds, Receptor, Cannabinoid, CB1 metabolism, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Self Administration, Ethanol administration & dosage, Ethanol pharmacology
- Abstract
Alcohol use disorder (AUD) affects >15 million people in the United States. Current pharmacotherapeutic treatments for AUD are only modestly effective, necessitating the identification of new targets for medications development. The cannabinoid receptor type 1 (CB1) has been a target of interest for the development of medications for substance use disorders and other compulsive disorders. However, CB1 antagonists/inverse agonists (e.g., rimonabant) have severe side effects that limit their clinical utility, including anxiety, depression, and suicide. Recent development of CB1 negative allosteric modulators (NAMs), including PSNCBAM-1, may provide an alternative mechanism of attenuating CB1 signaling with reduced side effects. PSNCBAM-1 has not yet been evaluated for effects in models of AUD. In this study, we investigated the effects of the CB1 NAM, PSNCBAM-1, in rodent models of AUD using adult male mice. PSNCBAM-1 dose-dependently attenuated oral ethanol self-administration (8 % w/v ethanol in water), significantly reducing ethanol rewards at a dose of 30 mg/kg, but not at 10 or 18 mg/kg. PSNCBAM-1 also dose-dependently attenuated palatable food self-administration (diluted vanilla Ensure), significantly reducing food rewards at 18 and 30 mg/kg PSNCBAM-1. PSNCBAM-1 did not affect conditioned place preference for 2 g/kg ethanol. These results suggest PSNCBAM-1 reduces ethanol-taking behavior via a nonspecific hypophagic effect and does not reduce the rewarding effects of ethanol., Competing Interests: Declaration of competing interest On behalf of all authors, the corresponding author states that there are no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF